5 results
RIPE Therapy - Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis - IDSA Guidelines

#Tuberculosis #ActiveTB #RIPE #Therapy
RIPE Therapy - Drug ... #ActiveTB #RIPE ... Therapy #regimens #medications ... #pharmacology # ... IDSA #Guidelines #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
inhibitors • Injection drug ... Treatment: Active ... TB: • (RIPE) isoniazid ... #TB #Diagnosis ... #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
inhibitors • Injection drug ... Treatment: Active ... TB: • (RIPE) isoniazid ... #TB #Diagnosis ... #Management #Treatment
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
Mycobacterium Tuberculosis ... prevent TB disease) Indications ... and molecular diagnostic ... #management #opportunistic ... infections #HIVAIDS #pharmacology
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
, INC risk PE, Pulmonary ... Adenocarcinoma Treatment ... lubricants • Pharmacologic ... muscarinic agonists • Active ... #Management